This is a preview of subscription content, access via your institution
Access options
Subscribe to this journal
Receive 51 print issues and online access
$199.00 per year
only $3.90 per issue
Buy this article
- Purchase on Springer Link
- Instant access to full article PDF
Prices may be subject to local taxes which are calculated during checkout
References
de Rooij, J. et al. Nature 396, 474–477 (1998).
McCormick, F. Nature 363, 15–16 (1993).
Farnsworth, C. L. et al. Nature 376, 524–527 (1995).
Mattingly, R. R. & Macara, I. G. Nature 382, 268–272 (1996).
Ebinu, J. O. et al. Science 280, 1082–1086 (1998).
Kitayama, H., Sugimoto, Y., Matsuzaki, T., Ikawa, Y. & Noda, M. Cell 56, 77–84 (1989).
Bos, J. L. EMBO J. 17, 6776–6782 (1998).
Zwartkruis, F. J., Wolthuis, R. M., Nabben, N. M., Franke, B. & Bos, J. L. EMBO J. 17, 5905–5912 (1998).
York, R. D. et al. Nature 392, 622–626 (1998).
Altschuler, D. L., Peterson, S. N., Ostrowski, M. C. & Lapetina, E. G. J. Biol. Chem. 270, 10373–10376 (1995).
Franke, B., Akkerman, J. W. & Bos, J. L. EMBO J. 16, 252–259 (1997).
Author information
Authors and Affiliations
Rights and permissions
About this article
Cite this article
Downward, J. New exchange, new target. Nature 396, 416–417 (1998). https://doi.org/10.1038/24743
Issue Date:
DOI: https://doi.org/10.1038/24743
This article is cited by
-
A phase II study of isoflavones, erlotinib, and gemcitabine in advanced pancreatic cancer
Investigational New Drugs (2011)